NCT05144347View on ClinicalTrials.gov

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

PHASE1TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions

Non-Hodgkin's Lymphoma (NHL)Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG

XL114

Tablets of XL114

Trial Locations (4)

15224

Exelixis Clinical #4, Pittsburgh

46250

Exelixis Clinical Site #1, Indianapolis

85719

Exelixis Clinical Site #3, Tucson

99208

Exelixis Clinical Site #2, Spokane

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Exelixis

INDUSTRY

NCT05144347 - Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter